- de Bie Rob M. A., Clarke Carl E., Espay Alberto J., Fox Susan H., Lang Anthony E. Initiation of pharmacological therapy in Parkinson's disease: when, why, and how Lancet neurology 2020;19 (5):452-461 [PubMed]
- Verschuur Constant V M, Suwijn Sven R, Boel Judith A, Post Bart, Bloem Bas R, van Hilten Johannes J, van Laar Teus, Tissingh Gerrit, Munts Alexander G, Deuschl Guenther, Lang Anthony E, Dijkgraaf Marcel G W, de Haan Rob J, de Bie Rob M A Randomized Delayed-Start Trial of Levodopa in Parkinson's Disease New England journal of medicine 2019;380 (4):315-324 [PubMed]
- Odekerken Vincent J. J., van Laar Teus, Staal Michiel J., Mosch Arne, Hoffmann Carel F. E., Nijssen Peter C. G., Beute Guus N., van Vugt Jeroen P. P., Lenders Mathieu W. P. M., Contarino M. Fiorella, Mink Marieke S. J., Bour Lo J., van den Munckhof Pepijn, Schmand Ben A., de Haan Rob J., Schuurman P. Richard, de Bie Rob M. A. Subthalamic nucleus versus globus pallidus bilateral deep brain stimulation for advanced Parkinson's disease (NSTAPS study): a randomised controlled trial Lancet neurology 2013;12 (1):37-44 [PubMed]
- Velseboer Daan C., Broeders Mark, Post Bart, van Geloven Nan, Speelman Johannes D., Schmand Ben, de Haan Rob J., de Bie Rob M. A. Prognostic factors of motor impairment, disability, and quality of life in newly diagnosed PD Neurology 2013;80 (7):627-633 [PubMed]
- Velseboer Daan C., de Haan Rob J., Wieling Wouter, Goldstein David S., de Bie Rob M. A. Prevalence of orthostatic hypotension in Parkinson's disease: a systematic review and meta-analysis Parkinsonism & related disorders 2011;17 (10):724-729 [PubMed]
2017- Professor of neurology
2011- Group leader Movement Disorders, Department of Neurology, Academic Medical Center, University of Amsterdam
2006- Neurologist, Movement Disorders
2005-2006 Clinical fellowship Movement Disorders, Toronto Western Hospital, Toronto, Ontario, Canada
1999-2005 Board Certification Neurology, Academic Medical Center, Amsterdam
1997-2002 Doctorate (Ph.D.), “Stereotactic pallidotomy in Parkinson’s disease”, University of Amsterdam
1993-1996 Medical Degree (M.D.) Faculty of Medicine, University of Amsterdam
Prof. PhD R.M.A. de Bie (Movement Disorders)
The Department of Neurology performs clinical and translational research within three research themes: infection & inflammation, cerebrovascular disorders, and movement disorders. The themes are imbedded in the nine translational research programs of Amsterdam Neuroscience, the research institute of neuroscience investigators in the Amsterdam area. All staff members of the Department of Neurology are involved in research and collaborate within Neuroscience Amsterdam, with other academic and non-academic hospitals, and with international research groups.
The research of the movement disorders group focuses on improving treatment, diagnosis, and insight in pathophysiology of movement disorders such as Parkinson’s disease, tremor, myoclonus, and dystonia. The group has a strong clinical research infrastructure to conduct large cohort studies and randomized controlled trials on interventions ranging from medication to botulinum toxin injections and Deep Brain Stimulation (DBS), aimed at solving burning clinical questions. Advanced neurophysiological measures and analysis techniques, intraoperative microrecording from nuclei situated deeply in the brain, and (functional) MRI are available to answer important diagnostic and pathophysiological research questions. The group is embedded in the neurodegeneration program of Amsterdam Neuroscience.
My research focuses on the improvement of treatment of Parkinson’s disease, including Deep Brain Stimulation (DBS), pharmacological treatment, and non-motor symptoms. In 2013, we completed a multicenter study that demonstrated the superiority of STN DBS compared to GPi DBS. Currently, my team is conducting a trial that compares DBS with Continuous Intrajejunal Levodopa Infusion for the treatment of advanced Parkinson’s disease (www.investamc.nl). We also conduct research to improve DBS hardware features ― e.g., steering DBS current.
In addition, I have initiated and lead a large RCT to assess a possible disease modifying effect of levodopa in early Parkinson’s disease (www.leapamc.nl). To recruit the 446 patients in 61 Dutch hospitals for this study, I established a National Clinical Research Network. In the same network, we investigate if cholinesterase inhibitors delay the progression of minor hallucinations to psychosis in Parkinson’s disease (www.chevalstudie.nl).
In collaboration with prof. Schmand, neuropsychologist, I investigate cognition in Parkinson’s disease. Notable projects include (1) cognitive impairment in the course of the disease and (2) an international collaborative Parkinson’s disease-MCI validation project directed by the AMC group, and (3) cognitive and psychiatric effects of DBS for Parkinson's disease. I have been following an incident cohort of Parkinson’s disease patients for 10 years now, which provides internationally acclaimed unique data regarding prognostication and disease course. I cooperate successfully with Drs. Barker and Williams-Gray, Cambridge, in projects regarding disease progression and prognostic models for PD.
S. de Vries
S. Van der Meijde-Bessems
Medewerkers buiten research programmes van afdeling Neurologie
Prof. PhD P.R. Schuurman (deep brain stimulation)
- Crediteurenadm. VUmc, p/a Profource Service Center
- Lysosomal Therapeutics Inc.
- Stichting Centre for Human Drug Research
- Stichting Parkinson Nederland
- UMC St. Radboud